OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript


OncoCyte Corporation (NASDAQ:OCX) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET

Company Participants

Stephanie Prince – IR, PCG Advisory

Josh Riggs – President & CEO

Conference Call Participants

Mike Matson – Needham

Jacob Krahenbuhl – Stephens

Vidyun Bais – BTIG

Operator

Thank you for standing by. My name is Tamika and I will be your conference operator today. At this time, I would like to welcome everyone to the OncoCyte Third Quarter 2023 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions].

Thank you. I would now hand today’s call over to Stephanie Prince of PCG Advisory. Please go ahead.

Stephanie Prince

Thank you, Tamika, and thank you to everyone joining us for today’s conference call to discuss OncoCyte’s third quarter 2023 financial results and recent operating highlights. If you have not seen today’s financial results press release, please visit the company’s website on the Investors page.

Before turning the call over to Josh Riggs, OncoCyte’s President and CEO, I would like to remind you that during this conference call the company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements.

We encourage you to review the company’s SEC filings, including, without limitation, the company’s Forms 10-K and 10-Q, which identify the specific Risk Factors that may cause actual results or events to differ materially from those described in these forward-looking statements.

Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. OncoCyte expressly disclaims any intent or obligation to update these forward-looking statements except as otherwise may be required under applicable law.

With that, I will turn the call over to Josh. Josh?



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *